The protective effects of trimetazidine on testicular ischemia and reperfusion injury in rats.
This study was designed to investigate the protective effect of trimetazidine [TMZ; 1-(2, 3, 4-trimethhoxibenzyl)-piperazine dihydrochloride], as an antioxidant agent, on torsion-detorsion-induced biochemical and histopathological changes in experimental testicular ischemia/reperfusion injury in rats. Twenty-seven male Wistar rats weighing 180-220 g were divided into five groups: control (C, n = 4), sham-operated (S, n = 4), ischemia (I, n = 6), ischemia-reperfusion (I/R, n = 6) and ischemia-reperfusion + trimetazidine (I/R + TMZ; n = 7). Control rats were used for basal normal values. In group I, 2 h torsion of the left testis was performed. In I/R and I/R + TMZ groups, following 2 h of torsion, 4 h detorsion of the testis was performed. In ischemia and I/R groups, physiologic saline was administered orally for 7 days, and the rats in I/R + TMZ group were pretreated orally with 5 mg/kg day TMZ for 7 days before inducing ischemia. At the end of each experiment, ipsilateral orchiectomies were performed for the tissue levels of malondialdehyde (MDA), glutathione peroxidase (GPx) enzyme activities and histopathological examinations in all groups. MDA levels were significantly reduced and GPx enzyme activities were significantly increased in testes in I/R+TMZ pretreated group compared to group I and I/R. The mean seminiferous tubular diameter (MSTD) and Johnsen's score were significantly better in I/R+TMZ group than groups I and I/R. Pretreatment with TMZ decreased germ cell apoptosis and caspase-3 expression in the ischemic testis. The present results show that TMZ has a protective activity in the testicular injury caused by I/R, and provide the first evidence of the role of TMZ for the prevention of I/R-induced testicular injury.
Pekcetin
Cetin
C
Department of Histology and Embryology, Dokuz Eylul University Medical School, Balcova, Izmi 35340, Turkey.
Ergur
Bekir Ugur
BU
Kiray
Muge
M
Bagriyanik
Alper
A
Tugyan
Kazim
K
Erbil
Guven
G
Ozogul
Candan
C
D000818:Animals; D017209:Apoptosis / Q000187:drug effects; D053148:Caspase 3 / Q000096:biosynthesis; D004195:Disease Models, Animal; D005500:Follow-Up Studies; D007150:Immunohistochemistry; D020287:In Situ Nick-End Labeling; D007511:Ischemia / Q000378:metabolism / Q000473:pathology / Q000517:prevention & control*; D008297:Male; D018384:Oxidative Stress / Q000187:drug effects; D051381:Rats; D017208:Rats, Wistar; D015427:Reperfusion Injury / Q000378:metabolism / Q000473:pathology / Q000517:prevention & control*; D013086:Spermatic Cord Torsion / Q000150:complications; D013094:Spermatozoa / Q000187:drug effects / Q000473:pathology; D013737:Testis / Q000098:blood supply*; D016896:Treatment Outcome; D014292:Trimetazidine / Q000627:therapeutic use*; D014665:Vasodilator Agents / Q000627:therapeutic use*
D014665:Vasodilator Agents; D053148:Caspase 3; D014292:Trimetazidine
Res Exp Med (Berl). 2000 Dec;200(1):43-51
11197921
Fertil Steril. 2006 Apr;85 Suppl 1:1111-7
16616082
Fertil Steril. 2005 Aug;84(2):468-73
16084892
Hormones. 1970;1(1):2-25
5527187
Pediatr Surg Int. 2006 May;22(5):435-41
16557390
Arch Med Res. 2006 Aug;37(6):700-8
16824928
J Thorac Cardiovasc Surg. 2001 Dec;122(6):1155-61
11726890
J Surg Res. 2006 Apr;131(2):199-203
16412470
Transpl Int. 1999;12(2):108-12
10363592
J Urol. 2004 Dec;172(6 Pt 2):2574-8
15538211
BJU Int. 2000 Aug;86(3):349-53
10930945
Mol Aspects Med. 2004 Feb-Apr;25(1-2):199-210
15051328
Pharmacol Res. 2004 Dec;50(6):623-9
15501702
J Mol Cell Cardiol. 2005 Dec;39(6):893-9
16243351
Scand J Urol Nephrol. 2003;37(6):456-60
14675916
Urology. 2005 Dec;66(6):1338-42
16360480
Pediatr Surg Int. 2007 Feb;23(2):177-81
16983563
Biol Reprod. 1997 Dec;57(6):1267-74
9408230
Ophthalmic Res. 2002 Sep-Oct;34(5):300-5
12381891
Circ J. 2006 Sep;70(9):1169-73
16936431
J Pediatr Surg. 2005 Mar;40(3):505-9
15793726
J Heart Lung Transplant. 2001 Oct;20(10):1115-22
11595567
Biol Reprod. 1993 Aug;49(2):401-7
8373967